Literature DB >> 17360897

Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.

Estelle Sontag1, Viyada Nunbhakdi-Craig, Jean-Marie Sontag, Ramon Diaz-Arrastia, Egon Ogris, Sanjana Dayal, Steven R Lentz, Erland Arning, Teodoro Bottiglieri.   

Abstract

Alzheimer's disease (AD) neuropathology is characterized by the accumulation of phosphorylated tau and amyloid-beta peptides derived from the amyloid precursor protein (APP). Elevated blood levels of homocysteine are a significant risk factor for many age-related diseases, including AD. Impaired homocysteine metabolism favors the formation of S-adenosylhomocysteine, leading to inhibition of methyltransferase-dependent reactions. Here, we show that incubation of neuroblastoma cells with S-adenosylhomocysteine results in reduced methylation of protein phosphatase 2A (PP2A), a major brain Ser/Thr phosphatase, most likely by inhibiting PP2A methyltransferase (PPMT). PP2A methylation levels are also decreased after ectopic expression of PP2A methylesterase in Neuro-2a (N2a) cells. Reduced PP2A methylation promotes the downregulation of B alpha-containing holoenzymes, thereby affecting PP2A substrate specificity. It is associated with the accumulation of both phosphorylated tau and APP isoforms and increased secretion of beta-secretase-cleaved APP fragments and amyloid-beta peptides. Conversely, incubation of N2a cells with S-adenosylmethionine and expression of PPMT enhance PP2A methylation. This leads to the accumulation of dephosphorylated tau and APP species and increased secretion of neuroprotective alpha-secretase-cleaved APP fragments. Remarkably, hyperhomocysteinemia induced in wild-type and cystathionine-beta-synthase +/- mice by feeding a high-methionine, low-folate diet is associated with increased brain S-adenosylhomocysteine levels, PPMT downregulation, reduced PP2A methylation levels, and tau and APP phosphorylation. We reported previously that downregulation of neuronal PPMT and PP2A methylation occur in affected brain regions from AD patients. The link between homocysteine, PPMT, PP2A methylation, and key CNS proteins involved in AD pathogenesis provides new mechanistic insights into this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360897      PMCID: PMC6672573          DOI: 10.1523/JNEUROSCI.3316-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  76 in total

Review 1.  Folate and Alzheimer: when time matters.

Authors:  Margareta Hinterberger; Peter Fischer
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

2.  The N-terminal Set-β Protein Isoform Induces Neuronal Death.

Authors:  Ephraim F Trakhtenberg; Melina I Morkin; Karan H Patel; Stephanie G Fernandez; Alan Sang; Peter Shaw; Xiongfei Liu; Yan Wang; Gregory M Mlacker; Han Gao; Dmitry Velmeshev; Susan M Dombrowski; Michael P Vitek; Jeffrey L Goldberg
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157

3.  Physiological regulation of tau phosphorylation during hibernation.

Authors:  Bo Su; Xinglong Wang; Kelly L Drew; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

4.  Protein phosphatase-1 inhibitor-3 is an in vivo target of caspase-3 and participates in the apoptotic response.

Authors:  Hua-Shan Huang; Ernest Y C Lee
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

Review 5.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

Review 6.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

Review 7.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  EPIGENETIC MECHANISMS IN MULTIPLE SCLEROSIS.

Authors:  Mar Gacias; Patrizia Casaccia
Journal:  Rev Esp Escler Mult       Date:  2014-03

9.  PP2A methylation controls sensitivity and resistance to β-amyloid-induced cognitive and electrophysiological impairments.

Authors:  Russell E Nicholls; Jean-Marie Sontag; Hong Zhang; Agnieszka Staniszewski; Shijun Yan; Carla Y Kim; Michael Yim; Caitlin M Woodruff; Erland Arning; Brandi Wasek; Deqi Yin; Teodoro Bottiglieri; Estelle Sontag; Eric R Kandel; Ottavio Arancio
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

10.  Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Lisa Montgomery; Erland Arning; Teodoro Bottiglieri; Estelle Sontag
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.